证券代码：688576 证券简称：西山科技 公告编号：2025-021 重庆西山科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 21 日 （二） 股东大会召开的地点：重庆市两江新区康美街道康竹路 2 号西山科技 B 栋行政楼 6 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 44 | | --- | --- | | 普通股股东人数 | 44 | | 2、出席会议的股东所持有的表决权数量 | 24,747,179 | | 普通股股东所持有表决权数量 | 24,747,179 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 54.7624 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.762 ...

Core Points - The annual general meeting of Chongqing Xishan Technology Co., Ltd. is scheduled for May 21, 2025, at 14:30, with a combination of on-site and online voting methods [3][5] - The meeting will cover several key proposals, including the 2024 Board of Directors' work report, the 2024 Supervisory Board work report, the 2024 financial settlement report, and the profit distribution plan for 2024 [5][8][9] - The company reported a net profit of 98,666,904.12 yuan for 2024, with a proposed cash dividend of 10.00 yuan per 10 shares, amounting to a total of 45,190,060.00 yuan, which represents 45.80% of the net profit [8][9] - The company’s total assets decreased from 2,318,065,640.21 yuan in 2023 to 1,925,782,570.99 yuan in 2024, primarily due to share buybacks and dividend distributions [25][26] - The company’s operating income for 2024 was 33,638.07 million yuan, down from 36,068.92 million yuan in 2023, while the net profit also decreased from 11,734.41 million yuan in 2023 to 9,866.69 million yuan in 2024 [25][26] Meeting Procedures - Attendees must arrive at least 30 minutes early for registration, and the meeting will be conducted under strict rules to maintain order and protect shareholder rights [2][4] - The agenda includes the election of vote counters, reading of meeting rules, and voting on various proposals [5][7] - The meeting will also include reports from independent directors and a session for shareholder questions and comments [7][13] Financial Performance - The company’s total liabilities increased, with a debt ratio of 8.35% in 2024 compared to 6.79% in 2023 [25][26] - Research and development expenses accounted for 16.42% of operating income in 2024, up from 12.89% in 2023, indicating a focus on innovation [25][26] - The company’s cash flow from operating activities was reported at 39,468.89 million yuan for 2024, down from 68,080.09 million yuan in 2023 [25][26]

重庆西山科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688576 证券简称：西山科技 1 | 2024 年年度股东大会会议须知 . | | --- | | 2024 年年度股东大会会议议程 . | | 议案一 . | | 《关于公司<2024年度董事会工作报告>的议案》 | | 议案二 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 7 | | 《关于公司<2024 年度监事会工作报告>的议案》 . | | 议案三 - | | 《关于公司<2024 年度财务决算报告>的议案》 | | 议案四 | | 《关于 2024 年度利润分配方案的议案》 | | 议案五 ………………………………………………………………………………………………………………………………………………………………………………………… 10 | | 《关于公司 2025 年度董事、高级管理人员薪酬方案的议案》 | | 议案六 | | 《关于公司 20 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-020 重庆西山科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 16 日（星期五）15:00-16:00 ? 会议召开地点：价值在线（www.ir-online.cn） ? 会议召开方式：网络互动方式 ? 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 5 月 16 日 前 访 问 网 址 https://eseb.cn/1o8423C4Eco 或使用微信扫描下方小程序码进行会前 提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普 遍关注的问题进行回答。 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年年度报告》 《2025 年第一季 度报告》。为便于广大投资者更加全面深入地了 ...

一、 说明会类型 证券代码：688576 证券简称：西山科技 公告编号：2025-020 重庆西山科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 五、 联系人及咨询电话 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年年度报告》《2025 年第一季 度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司计划于 2025 年 5 月 16 日（星期五）15:00-16:00 在"价值在线" （www.ir-online.cn）举办重庆西山科技股份有限公司 2024 年度暨 2025 年第一 会议召开时间：2025 年 5 月 16 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 ...

Revenue Performance - In 2024, the company's operating revenue was 336,380,651.11 yuan, a decrease of 6.74% compared to 2023's 360,689,152.26 yuan, indicating challenges in market expansion and potential market share erosion [1] - The surgical power consumables segment grew steadily, with a year-on-year increase of 15.69%, while the surgical power devices and new product equipment saw revenue declines due to external factors such as delayed bidding [1] - Certain products, like breast biopsy needles, experienced a slight revenue drop due to centralized procurement impacts, although neurosurgery, orthopedics, and ENT consumables showed significant growth exceeding 40% [1] Profitability Analysis - The net profit attributable to shareholders was 98,666,904.12 yuan, down 15.92% from 117,344,082.20 yuan in 2023, influenced by increased R&D expenses and reduced government subsidies [2] - R&D expenses rose to 55,239,983.73 yuan, an 18.79% increase, which compressed profit margins, while government subsidies fell from 14,461,373.20 yuan in 2023 to 4,643,974.74 yuan in 2024 [2] - The non-GAAP net profit decreased by 22.45% to 71,710,314.84 yuan, indicating weakened core business profitability and challenges in enhancing main business earnings [2] Earnings Per Share - Basic earnings per share (EPS) for 2024 was 1.97 yuan, down 22.13% from 2.53 yuan in 2023, directly affecting shareholder returns [3] - The non-GAAP EPS fell by 28.14% to 1.43 yuan, further highlighting the decline in profitability and challenges in operational stability [3] Expense Management - Total expenses remained relatively stable, with sales expenses at 87,641,744.80 yuan, a slight increase of 0.06% from 2023, and management expenses rising by 2.87% to 25,253,817.19 yuan [3] - R&D expenses accounted for 16.42% of operating revenue, up from 12.89% in 2023, reflecting a commitment to innovation despite short-term profit impacts [3] R&D Personnel - The number of R&D personnel increased by 19% to 144, indicating a focus on enhancing R&D capabilities [4] - The educational background of R&D staff includes 7 PhDs, 48 Master's degrees, and 84 Bachelor's degrees, suggesting a need for further optimization to attract high-end talent [4] Cash Flow Analysis - Net cash flow from operating activities decreased by 42.03% to 39,468,869.13 yuan, primarily due to increased expenditures on materials, salaries, taxes, and R&D [5] - Cash flow from investing activities improved significantly to 309,379,187.15 yuan, compared to -1,312,509,545.87 yuan in 2023, indicating effective adjustments in investment strategy [5] - Cash flow from financing activities was -502,774,371.32 yuan, reflecting increased outflows due to share buybacks and dividends, emphasizing a focus on shareholder returns [5]

Core Insights - The company reported a revenue of 336 million yuan and a net profit attributable to shareholders of 98.67 million yuan for the reporting period [1] - The company maintains its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, focusing on business line layout and expansion [1] Financial Performance - Revenue for the reporting period was 336 million yuan, with a net profit of 98.67 million yuan [1] - R&D expenses amounted to 55.24 million yuan, reflecting an 18.79% year-on-year increase [2] R&D Investment - The number of R&D personnel increased by 19% year-on-year, indicating a strong commitment to innovation [2] - R&D investment as a percentage of revenue has grown from 11.42% in 2022 to 16.42% in 2024, demonstrating a consistent increase in focus on R&D [2] Strategic Direction - The company plans to continue its dual growth strategy of "internal development" and "external expansion" while adhering to its strategic positioning [2] - The product strategy will focus on the integration of endoscopic systems, surgical power devices, energy surgical equipment, and other extensions in the minimally invasive surgery field [2]

Core Viewpoint - Xishan Technology (688576) reported a revenue of 336 million yuan and a net profit attributable to shareholders of 98.67 million yuan for 2024, with a basic earnings per share of 1.97 yuan [1] Financial Performance - The company proposed a profit distribution plan of 10 yuan per 10 shares, totaling 45.19 million yuan in cash dividends, which accounts for 45.80% of the net profit for 2024 [1] - The total amount for cash dividends and share buybacks reached 499.5 million yuan, representing 501.81% of the net profit for the period [1] Business Strategy and Market Position - The company maintains its strategic positioning as a "provider of overall solutions for minimally invasive surgical tools," focusing on business line layout and expansion [1] - The company has seen steady growth in surgical power consumables, particularly in neurosurgery, orthopedics, and ENT fields, with consumable revenue increasing by over 40% year-on-year [1] Product Development and R&D Investment - Significant growth was noted in energy surgical equipment, with ultrasound bone knife consumables and plasma device consumables showing remarkable increases, particularly the plasma products which achieved revenue breakthroughs for the first time [2] - The company increased its R&D personnel by 19% and R&D expenses by 18.79%, reaching 55.24 million yuan in 2024 [2] - R&D investment as a percentage of revenue has consistently increased from 11.42% in 2022 to 16.42% in 2024, indicating a strong commitment to innovation [2] Technological Advancements - The company made significant breakthroughs in the field of flexible endoscopes, overcoming core technical bottlenecks in electronic digestive tract flexible endoscopes, with product registration progressing smoothly [2] Future Growth Strategy - The company plans to continue increasing R&D investment, focusing on hospital user development and usage enhancement, while actively expanding into overseas markets [3] - The dual growth strategy of "internal development" and "external expansion" will be pursued, supported by a "innovation-driven" and "capital-driven" approach [3]

证券代码：688576 证券简称：西山科技 公告编号：2025-019 重庆西山科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 21 日 14 点 30 分 召开地点：重庆市两江新区康美街道康竹路 2 号西山科技 B 栋行政楼 6 楼 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 21 日 股东大会召开日期：2025年5月21日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 至2025 年 5 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-015 重庆西山科技股份有限公司 第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第四届监事会第四次会议于 2025 年 4 月 28 日 15:30 以现场结合通讯方式在公司会议室召开。应出席会议监 事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。会议通知 于 2025 年 4 月 18 日通过书面方式和电话等方式发出。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《重庆西山科技股份有限公司公司章程》（以下简称"《公司章程》"）的有关 规定。 二、监事会会议审议情况 会议经过审核、表决，通过以下决议： （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 经审议，监事会认为公司 2024 年度监事会工作报告符合法律、行政法规、 规范性文件和《公司章程》相关规定。因此，监事会一致同意本议案。 表决情况 ...